Insiders Favor Dave And 2 More High Growth Companies
Over the last 7 days, the United States market has risen by 4.9%, contributing to a notable 21% increase over the past year, with earnings expected to grow by 17% annually in the coming years. In this thriving environment, companies with high insider ownership often attract attention as they signal confidence from those closest to the business; Dave and two other high-growth companies exemplify this trend.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.1% | 59.9% |
| Super Micro Computer (SMCI) | 12.8% | 22.4% |
| Nu Holdings (NU) | 22.8% | 20.2% |
| Karman Holdings (KRMN) | 15.3% | 52.6% |
| IREN (IREN) | 13.6% | 40.2% |
| ERock (EROC) | 20.1% | 56.3% |
| Corcept Therapeutics (CORT) | 10.8% | 44.8% |
| Cerebras Systems (CBRS) | 11% | 73.7% |
| AppLovin (APP) | 23.2% | 21.7% |
Let's uncover some gems from our specialized screener.
Dave (DAVE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Dave Inc. operates a financial services platform offering a range of financial products and services in the United States, with a market cap of approximately $5.07 billion.
Operations: The company's revenue is primarily generated from its service-based and transaction-based operations, amounting to $604.62 million.
Insider Ownership: 18.1%
Revenue Growth Forecast: 20.4% p.a.
Dave Inc. has demonstrated strong financial growth, with earnings increasing by 329% over the past year and revenue forecasted to grow at 20.4% annually, outpacing the US market's average. Despite being dropped from several Russell indices in June 2026, it was added to key S&P indices in May 2026. The recent appointment of Gopi Kuchimanchi as CTO aims to bolster technological advancements for sustained growth and profitability amidst a backdrop of high insider ownership but notable recent insider selling.
- Delve into the full analysis future growth report here for a deeper understanding of Dave.
- Our valuation report unveils the possibility Dave's shares may be trading at a premium.
ImmunityBio (IBRX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ImmunityBio, Inc. is a biotechnology company that develops and commercializes next-generation immunotherapies to activate the immune system against cancer and infectious diseases, with a market cap of $7.28 billion.
Operations: ImmunityBio focuses on creating and marketing advanced immunotherapies aimed at stimulating the immune system for long-lasting defense against cancer and infectious diseases.
Insider Ownership: 28.2%
Revenue Growth Forecast: 49.7% p.a.
ImmunityBio reported significant revenue growth, with second-quarter earnings rising to US$51.24 million from US$26.43 million a year ago, though net losses increased substantially. Its high insider ownership aligns with forecasts of strong annual profit and revenue growth, expected to outpace the market. Recent marketing authorizations for ANKTIVA in the UAE expand its global footprint despite being dropped from several Russell indices in June 2026, indicating mixed market sentiment amidst strategic product developments.
- Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report.
- Our valuation report unveils the possibility ImmunityBio's shares may be trading at a discount.
Ethos Technologies (LIFE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ethos Technologies Inc. operates as a third-party administrator for insurance policies in the United States with a market capitalization of $1.44 billion.
Operations: Ethos Technologies Inc. generates revenue by offering third-party administration services for insurance policies across the United States.
Insider Ownership: 22%
Revenue Growth Forecast: 20.8% p.a.
Ethos Technologies showcases substantial revenue growth, with second-quarter earnings reaching US$189.56 million compared to US$88.85 million a year prior, though net income saw minimal improvement. The company's high insider ownership and strategic innovations like the ChatGPT app integration underpin forecasts of robust annual profit and revenue growth, outpacing market averages. Recently announced share buyback plans further reflect confidence in its valuation despite a volatile share price and previous net losses this year.
- Take a closer look at Ethos Technologies' potential here in our earnings growth report.
- Insights from our recent valuation report point to the potential undervaluation of Ethos Technologies shares in the market.
Where To Now?
- Embark on your investment journey to our 170 Fast Growing US Companies With High Insider Ownership selection here.
- Searching for a Fresh Perspective? AI is about to change healthcare. These 128 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com